|
注册号: Registration number: |
ChiCTR2300073690 |
|
最近更新日期: Date of Last Refreshed on: |
2023-09-15 16:54:15 |
|
注册时间: Date of Registration: |
2023-07-19 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
鼻中隔成形术后鼻中隔固位器与鼻中隔黏膜缝合的疗效比较研究 |
|
Public title: |
Comparative study of nasal septum retainer and trans-septal suturing in patients undergoing septoplasty: a randomized controlled trial |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
鼻中隔成型术后鼻中隔固位器与鼻中隔黏膜缝合的疗效比较研究 |
|
Scientific title: |
Comparative study of nasal septum retainer and trans-septal suturing in patients undergoing septoplasty: a randomized controlled trial |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
王超 |
研究负责人: |
王卫华 |
|
Applicant: |
Chao Wang |
Study leader: |
Weihua Wang |
|
申请注册联系人电话: Applicant telephone: |
+86 561 558 9861 |
研究负责人电话:
Study leader's |
+86 189 1830 0635 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
tscgrr@163.com |
研究负责人电子邮件: Study leader's E-mail: |
whwangcn@tongji.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海市浦东新区即墨路150号 |
研究负责人通讯地址: |
上海市浦东新区即墨路150号 |
|
Applicant address: |
150 Jimo Road, Pudong New Area, Shanghai |
Study leader's address: |
150 Jimo Road, Pudong New Area, Shanghai |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
上海东方医院 |
||
|
Applicant's institution: |
Shanghai East Hospital |
||
|
研究负责人所在单位: |
上海东方医院 |
||
|
Affiliation of the Leader: |
Shanghai East Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
[2023] 研预审第(025)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
上海市东方医院(同济大学附属东方医院) 医学伦理委员会 |
||
|
Name of the ethic committee: |
Institutional Review Board of Shanghai East Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-06-16 00:00:00 | ||
|
伦理委员会联系人: |
徐增光 |
||
|
Contact Name of the ethic committee: |
Zengguang Xu |
||
|
伦理委员会联系地址: |
上海市浦东新区即墨路 150 号 |
||
|
Contact Address of the ethic committee: |
150 Jimo Road, Pudong New Area, Shanghai |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 21 6156 9829 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
上海市东方医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Shanghai East Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
上海市浦东新区即墨路150号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
150 Jimo Road, Pudong New Area, Shanghai |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自筹 |
||||||||||||||||||||||
|
Source(s) of funding: |
None |
||||||||||||||||||||||
|
研究疾病: |
鼻中隔偏曲 |
||||||||||||||||||||||
|
Target disease: |
Deviated nasal septum |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
治疗新技术临床试验 | ||||||||||||||||||||||
|
Study phase: |
New Treatment Measure Clinical Study |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
比较鼻中隔固位夹与鼻中隔黏膜缝合的术后操作用时。 |
||||||||||||||||||||||
|
Objectives of Study: |
The purpose of this trial is to compare the closure time spent on nasal septum retainer and trans-septal suturing in patients undergoing septoplasty. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1. 同时伴有鼻前庭炎、慢性鼻窦炎、或鼻腔恶性肿瘤等疾病; 2. 患者凝血功能异常或患有其他血液系统疾病; 3. 既往有鼻中隔相关手术史; 4. 妊娠期女性; 5.无法耐受全身麻醉的患者; 6.患者有慢性疾病史,且控制欠佳。 7.心理、精神疾病患者; 8.研究人员认为存在任何不适合入选或影响受试者参与研究的其它因素。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Simultaneously accompanied by diseases such as nasal vestibulitis, chronic sinusitis, or malignant tumors in the nasal cavity; 2. The patient has abnormal coagulation function or suffers from other blood system diseases; 3. Previous history of nasal septum related surgery; 4. Pregnant women; 5. Patients who cannot tolerate general anesthesia; 6. The patient has a history of chronic diseases and poor control. 7. Patients with psychological or mental illnesses; 8. The researchers believe that there are any other factors that are not suitable for inclusion or that affect the participants' participation in the study. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-06-17 00:00:00至 To 2024-05-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2023-07-20 00:00:00 至 To 2023-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
研究者按照1:1的比例使用随机数表将患者分到鼻中隔固位夹组和鼻中隔黏膜缝合组。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
The randomization is performed by operator with random number table method and the allocation ratio is 1:1 between septum retainer group and trans-septal suturing group. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
对评估者设盲。 |
|
Blinding: |
The evaluator is blinded to treatment allocation. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
不共享 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例报告表(CRF):我们将使用标准化的病例报告表(CRF)记录每位参与者的所有相关信息。这将包括人口统计数据、医疗历史、特定研究数据和任何不良事件。CRF将由经过培训的研究员或研究协调员完成。 电子数据采集(EDC):CRF中的所有数据将被录入电子数据采集系统。该系统将确保数据录入的准确性和效率,并允许实时数据监控。EDC系统将受密码保护,只有经授权的人员才能获取。 数据验证:将对录入EDC系统的数据进行验证,以确保数据的准确性和完整性。这将包括对数据值的范围检查和对缺失数据的检查。在进行数据分析之前,将解决识别出的任何差异。 数据安全:所有数据将安全地存储,以维护参与者的机密性。这将包括电子数据的加密和纸质文件的安全存储。所有数据将被匿名化或用化名化,以确保参与者的隐私。 数据分析:数据将按照统计分析计划进行分析。任何对计划的改动都将被记录并进行合理的解释。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Report Form (CRF): A standardized CRF will be used to record all relevant information for each participant. This will include demographic data, medical history, study-specific data, and any adverse events. The CRF will be completed by trained investigators or research coordinators. Electronic Data Capture (EDC): All data from the CRF will be entered into an electronic data capture system. This system will ensure accurate and efficient data entry and will allow for real-time data monitoring. The EDC system will be password protected, and access will only be given to authorized personnel. Data Validation: Data entered into the EDC system will be validated for accuracy and completeness. This will include range checks for data values and checks for missing data. Any discrepancies identified will be resolved before the data analysis. Data Security: All data will be stored securely to maintain participant confidentiality. This will include encryption of electronic data and secure storage of paper documents. All data will be anonymized or pseudonymized to ensure participant privacy. Data Analysis: The data will be analyzed as per the statistical analysis plan. Any changes to the plan will be documented and justified. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |